NO831098L - Peptider med spesifiteten til munn- og klovsyke-virus-antigener - Google Patents
Peptider med spesifiteten til munn- og klovsyke-virus-antigenerInfo
- Publication number
- NO831098L NO831098L NO831098A NO831098A NO831098L NO 831098 L NO831098 L NO 831098L NO 831098 A NO831098 A NO 831098A NO 831098 A NO831098 A NO 831098A NO 831098 L NO831098 L NO 831098L
- Authority
- NO
- Norway
- Prior art keywords
- peptide
- fmdv
- peptides
- amino acid
- subtypes
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 147
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 95
- 239000000427 antigen Substances 0.000 title claims description 22
- 102000036639 antigens Human genes 0.000 title claims description 22
- 108091007433 antigens Proteins 0.000 title claims description 22
- 201000010099 disease Diseases 0.000 title description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 5
- 244000061408 Eugenia caryophyllata Species 0.000 title 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 title 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 67
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 claims description 36
- 241000700605 Viruses Species 0.000 claims description 36
- 101710132601 Capsid protein Proteins 0.000 claims description 34
- 101710197658 Capsid protein VP1 Proteins 0.000 claims description 33
- 101710108545 Viral protein 1 Proteins 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 18
- 230000000890 antigenic effect Effects 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 9
- 238000010790 dilution Methods 0.000 claims description 9
- 239000012895 dilution Substances 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 230000003472 neutralizing effect Effects 0.000 claims description 8
- 230000008878 coupling Effects 0.000 claims description 5
- 238000010168 coupling process Methods 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 102100031974 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Human genes 0.000 claims description 2
- 101000703754 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 claims description 2
- 101000641077 Homo sapiens Diamine acetyltransferase 1 Proteins 0.000 claims description 2
- 101000713305 Homo sapiens Sodium-coupled neutral amino acid transporter 1 Proteins 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 102100030100 Sulfate anion transporter 1 Human genes 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 24
- 238000005259 measurement Methods 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 19
- 102000014914 Carrier Proteins Human genes 0.000 description 14
- 108010078791 Carrier Proteins Proteins 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 9
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- JXCHMDATRWUOAP-UHFFFAOYSA-N diisocyanatomethylbenzene Chemical compound O=C=NC(N=C=O)C1=CC=CC=C1 JXCHMDATRWUOAP-UHFFFAOYSA-N 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 229940031626 subunit vaccine Drugs 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- -1 3 -dimethylaminopropyl Chemical group 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 241000252095 Congridae Species 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 102100034274 Diamine acetyltransferase 1 Human genes 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 101000640813 Homo sapiens Sodium-coupled neutral amino acid transporter 2 Proteins 0.000 description 1
- 101000716973 Homo sapiens Thialysine N-epsilon-acetyltransferase Proteins 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 1
- SENJXOPIZNYLHU-IUCAKERBSA-N Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-IUCAKERBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000025414 Pentalagus furnessi Species 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 102100020926 Thialysine N-epsilon-acetyltransferase Human genes 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 241000723873 Tobacco mosaic virus Species 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003670 easy-to-clean Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108010000761 leucylarginine Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 108010006230 protelin Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/22—Viral peptide or viral protein
- Y10S930/222—Foot and mouth disease related
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8209041 | 1982-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO831098L true NO831098L (no) | 1983-09-27 |
Family
ID=10529329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO831098A NO831098L (no) | 1982-03-26 | 1983-03-25 | Peptider med spesifiteten til munn- og klovsyke-virus-antigener |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4605512A (fr) |
| EP (1) | EP0090581A3 (fr) |
| JP (1) | JPS58213723A (fr) |
| AU (1) | AU1255383A (fr) |
| DK (1) | DK139083A (fr) |
| ES (1) | ES8500997A1 (fr) |
| IL (1) | IL68201A0 (fr) |
| NO (1) | NO831098L (fr) |
| PT (1) | PT76451B (fr) |
| ZA (1) | ZA831854B (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1983003547A1 (fr) * | 1982-04-14 | 1983-10-27 | Bittle, James, L. | Antigene synthetique du picornavirus |
| US5230888A (en) * | 1982-05-06 | 1993-07-27 | Massachusetts Institute Of Technology | Production of neutralizing antibodies by polypeptide VP1 of enteroviruses and by oligopeptide fragments of polypeptide VP1 |
| NZ205924A (en) * | 1982-10-11 | 1987-07-31 | Nat Biolog Standards Board | Synthetic polypeptide: fragment of structural capsid protein; vaccine; method for diagnosis |
| GB8301928D0 (en) * | 1983-01-24 | 1983-02-23 | Nicholson B H | Process for producing polypeptides |
| US4708871A (en) * | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| WO1984003506A1 (fr) * | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Sequences d'acides amines antigeniquement actives |
| NZ207394A (en) * | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| AU576750B2 (en) * | 1983-03-08 | 1988-09-08 | Chiron Mimotopes Pty Ltd | Method of determining antigenically active amino acid sequences |
| AU573574B2 (en) * | 1983-03-08 | 1988-06-16 | Chiron Mimotopes Pty Ltd | Immunogenic deteminants of foot and mouth disease virus |
| US4894332A (en) * | 1985-03-27 | 1990-01-16 | Biogen, Inc. | DNA sequences coding for Mycoplasma hypopneumoniae surface antigens, methods of use to make the corresponding proteins |
| US4732971A (en) * | 1985-06-03 | 1988-03-22 | Eli Lilly And Company | Synthetic vaccines for foot and mouth disease |
| DE3813821A1 (de) * | 1988-04-22 | 1989-11-02 | Hoechst Ag | Synthetische vakzine gegen die maul- und klauenseuche und verfahren zu deren herstellung |
| US6024964A (en) * | 1985-06-24 | 2000-02-15 | Hoechst Aktiengesellschaft | Membrane anchor/active compound conjugate, its preparation and its uses |
| US6074650A (en) * | 1985-06-24 | 2000-06-13 | Hoechst Aktiengesellschaft | Membrane anchor/active compound conjugate, its preparation and its uses |
| DE3855458T2 (de) * | 1987-12-10 | 1996-12-05 | Jolla Cancer Res Found | Verfahren zur herstellung von conformationnell stabilisierten zelladhäsionspeptiden |
| US5827821A (en) | 1987-12-10 | 1998-10-27 | The Burnham Institute | Conformationally stabilized cell adhesion peptides |
| US5864008A (en) * | 1988-03-25 | 1999-01-26 | James; Stephen | Peptides derived from foot-and-mouth disease virus, pharmaceutical compositions, and methods for using the peptides |
| EP0420913B1 (fr) * | 1988-06-14 | 1995-11-15 | Cell Med, Inc. | Reactifs immunologiques cellulaires heterofonctionnels, vaccins les contenant et leurs modes d'utilisation |
| DE69126871T2 (de) * | 1990-04-06 | 1998-03-12 | Jolla Cancer Res Found | Verfahren und verbindung zur behandlung von thrombose |
| US5780303A (en) * | 1990-04-06 | 1998-07-14 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
| US6521594B1 (en) | 1990-04-06 | 2003-02-18 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
| US5648330A (en) * | 1990-04-06 | 1997-07-15 | La Jolla Cancer Research Foundation | Method and composition for treating vascular graft occlusion |
| US5672585A (en) * | 1990-04-06 | 1997-09-30 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
| US5612311A (en) | 1990-04-06 | 1997-03-18 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
| DE19638044A1 (de) * | 1996-09-18 | 1998-03-19 | Bayer Ag | Immunogene Peptide von Maul- und Klauenseuchen-Viren |
| CN101565458B (zh) * | 2009-06-04 | 2014-01-08 | 中牧实业股份有限公司 | 一种动物用肽疫苗及其制备 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0040922A1 (fr) * | 1980-05-12 | 1981-12-02 | Biogen N.V. | Séquences d'ADN, molécules d'ADN recombinant et procédé pour la production de polypeptides à spécificité d'antigènes viraux de la fièvre aphteuse |
| IL62553A (en) * | 1980-06-06 | 1984-12-31 | Biogen Nv | Vectors comprising dna sequences comprising at least one promoter and operator derived from bacteriophage ypsilon and methods for producing such recombinant dna molecules and cloning vectors |
| FI83662C (fi) * | 1980-07-17 | 1991-08-12 | Scripps Clinic Res | Diagnostik antikropp och foerfarande foer dess framstaellning. |
| NL8104297A (nl) * | 1980-09-18 | 1982-04-16 | Wellcome Found | Dna-moleculen met polynucleotidevolgordes die geheel of ten dele overeenkomen met mond- en klauwzeervirus rna, alsmede werkwijze ter bereiding daarvan. |
| PT74811B (en) * | 1981-04-29 | 1983-10-26 | Biogen Nv | Bacillus cloning vectors recombinant dna molecules bacillus hosts transformed with them and methods for expressing foreign dna sequences and producing polypeptides coded thereby |
| WO1983003547A1 (fr) * | 1982-04-14 | 1983-10-27 | Bittle, James, L. | Antigene synthetique du picornavirus |
| EP0105481A1 (fr) * | 1982-09-30 | 1984-04-18 | The Wellcome Foundation Limited | Antigènes et vaccins contenant ces antigènes |
-
1983
- 1983-03-16 ZA ZA831854A patent/ZA831854B/xx unknown
- 1983-03-17 AU AU12553/83A patent/AU1255383A/en not_active Abandoned
- 1983-03-22 EP EP83301589A patent/EP0090581A3/fr not_active Withdrawn
- 1983-03-23 IL IL68201A patent/IL68201A0/xx unknown
- 1983-03-24 JP JP58048067A patent/JPS58213723A/ja active Pending
- 1983-03-25 PT PT76451A patent/PT76451B/pt unknown
- 1983-03-25 US US06/478,901 patent/US4605512A/en not_active Expired - Fee Related
- 1983-03-25 ES ES520997A patent/ES8500997A1/es not_active Expired
- 1983-03-25 NO NO831098A patent/NO831098L/no unknown
- 1983-03-25 DK DK139083A patent/DK139083A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US4605512A (en) | 1986-08-12 |
| IL68201A0 (en) | 1983-06-15 |
| AU1255383A (en) | 1983-09-29 |
| ES520997A0 (es) | 1984-11-01 |
| EP0090581A2 (fr) | 1983-10-05 |
| EP0090581A3 (fr) | 1984-10-24 |
| DK139083A (da) | 1983-09-27 |
| PT76451B (en) | 1986-03-11 |
| DK139083D0 (da) | 1983-03-25 |
| ES8500997A1 (es) | 1984-11-01 |
| PT76451A (en) | 1983-04-01 |
| ZA831854B (en) | 1984-01-25 |
| JPS58213723A (ja) | 1983-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO831098L (no) | Peptider med spesifiteten til munn- og klovsyke-virus-antigener | |
| Bittle et al. | Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence | |
| NO313917B1 (no) | Antigen-presenterende kapsid med fusert MS2-kappeprotein | |
| KR20010053042A (ko) | 구제역에 대한 합성 펩티드 백신 | |
| WO1999067294A1 (fr) | Complexe antigenique comprenant un peptide immunostimulateur, cd4 et un domaine de recepteur de chemokine pour traiter vih et des maladies immunitaires | |
| JPH05262667A (ja) | ウイルス抗原を用いるワクチン | |
| KR100927221B1 (ko) | Ｅ형 간염 바이러스의 폴리펩티드 단편, 그를 이용한 백신조성물 및 진단용 키트 | |
| EP0661999B1 (fr) | Vaccins destines a lutter contre le virus immunodeficitaire felin | |
| EA022788B1 (ru) | Новые терапевтические и диагностические средства | |
| US7604961B2 (en) | VP1 of foot-and-mouth disease virus | |
| Frangione-Beebe et al. | Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide | |
| CN102180952A (zh) | 口蹄疫病毒抗原多肽、融合抗原多肽及疫苗 | |
| CA1271717A (fr) | Polypeptides utiles dans la vaccination contre les enterovirus | |
| RU2181379C2 (ru) | Пептид (варианты) и способ его производства, фармацевтическое средство, антитело и способ его производства | |
| US4857634A (en) | Peptides useful in vaccination against enteroviruses | |
| JP2004121266A (ja) | コンビナトリアルポリペプチド抗原 | |
| González et al. | Comparison of capsid protein VP1 of the viruses used for the production and challenge of foot-and-mouth disease vaccines in Spain | |
| Bachrach | Foot-and-mouth disease and its antigens | |
| CN115850398B (zh) | 新型冠状病毒奥密克戎系列变异株的多肽组合物及其应用 | |
| JP3940676B2 (ja) | 日本脳炎ウイルスに対するキメラｔヘルパー細胞−ｂ細胞ペプチドワクチン | |
| CA1287447C (fr) | Peptides utiles dans les vaccins contre des enterovirus | |
| CA2143187C (fr) | Vaccins anti-virus d'immunodeficience chez les felins | |
| Kuprianova et al. | Synthetic peptide constructs on the basis of immunoactive fragments of the A22 strain VP1 of the foot-and-mouth disease virus | |
| EP0551689A2 (fr) | Peptides cycliques du déterminant principal de neutralisation (PND) du HIV | |
| NO164246B (no) | Analogifremgangsmaate for fremstilling av et terapeutisk aktivt antigent peptid. |